Mitoxantrone for venetoclax-resistant AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a re-purposed drug, mitoxantrone, for people whose AML has not responded to or has come back after standard frontline treatment. The goal is to see if this older drug can help overcome resistance to venetoclax.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML and have already tried venetoclax with azacitidine or decitabine.
- Your leukemia either came back after treatment or didn't get better.
- Your heart, kidneys, and liver are working well enough (doctors will check with tests).
- You haven't had certain types of chemotherapy called anthracyclines before.
- You are willing to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests whether azacitidine (CC-486) plus venetoclax can help people with acute myeloid leukemia (AML) that is not APL. It’s designed to find safe dosing and see how well the combination works for newly diagnosed or relapsed/refractory AML.
This trial tests a combination of three drugs (mitoxantrone liposome, cytarabine, and venetoclax) for people with AML that has returned or not responded to treatment. The goal is to see if this combination can help control the leukemia.
This trial tests a combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as a first treatment for people newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works better than standard care.
This trial tests a combination of three drugs for treating newly diagnosed AML in older or frailer patients. The goal is to see if this combination is safe and effective, providing a gentler option for those who cannot handle standard intensive chemotherapy.
This clinical trial tests a combination of three drugs: a liposomal form of mitoxantrone (a type of chemotherapy), cytarabine (another chemo drug), and venetoclax (a targeted therapy). The goal is to see if this combination is safe and works well for older adults (ages 60-70) who have just been diagnosed with AML and cannot have standard intensive chemotherapy.
This trial compares two different combinations of chemotherapy drugs for adults newly diagnosed with acute myeloid leukemia (AML). One combination uses newer targeted drugs, while the other is a standard treatment. The goal is to see which approach works better.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.